Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VENCLEXTA, VENCLEXTA STARTING PACK (Abbvie Pty Ltd)
Product name
VENCLEXTA, VENCLEXTA STARTING PACK
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
222 working days (255)
Active ingredients
venetoclax
Registration type
EOI
Indication
Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma
VENCLEXTA (film coated tablet) in combination with obinutuzumab is now also indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who are considered unfit or unsuitable for chemo-immunotherapy.